$KZIA why I'm bullish on this brain cancer NASDAQ biotech gem that's extremely undervalued. I believe a new drug application will be submitted by the end of 2024. Less than 30M shares and at $3 we'd still be valued at less than 100M. Many other biotechs in the cancer space with a similar pipeline for eye cancer are valued at 150 to 350M. Current share price is .35 a share.
Read next
From Legacy to Ledger: Nasdaq and TD Securities Join Forces to Pioneer Tokenized Stock Marketspichat · 
This underground AI factory in Germany is unforgettable.jakaria890 · 
Bitcoin Price Correlation with Traditional Markets | BTC VS NASDAQ, Gold, and Global Money Supply | August 2026dalz · 
NASDAQ New Setup and Wild Strategiesbreak-out-trader ·
From @josephlizyness